Scarica l'app Stockscreener
1.67
2.91%
-0.05
Dopo l'orario di chiusura:
1.70
0.03
+1.80%
Pulmatrix Inc Borsa (PULM) Ultime notizie
Trading the Move, Not the Narrative: (PULM) Edition - Stock Traders Daily
Halper Sadeh LLC is Investigating Whether SLP, HUN, OLN, PULM are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Pulmatrix Inc (PULM) Institutional Confidence - TradingKey
Pulmatrix (NASDAQ: PULM) to Merge with Eos; 75.2M Shares to Be Issued - Stock Titan
PULMPulmatrix Inc Latest SEC Filings - Finviz
PULM Q2 2025 Earnings: Continued R&D Investment Drives Net Loss as Pipeline AdvancesBanking Earnings Report - dars.gov.et
Enterprise value to EBITDA forward of Pulmatrix, Inc. – NASDAQ:PULM - TradingView
Pulmatrix | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactionsmoomoo - Moomoo
Pulmatrix (PULM) Holds Near Support After Modest DeclineStop Loss Guidance - dars.gov.et
(PULM) Volatility Zones as Tactical Triggers - Stock Traders Daily
Pulmatrix Inc Actuals & Estimates (NASDAQ:PULM) - TradingView
Pulmatrix Inc Actuals & Estimates (LS:A3DWEE) - TradingView
Enterprise value to revenue forward of Pulmatrix, Inc. – NASDAQ:PULM - TradingView
Price to earnings forward of Pulmatrix, Inc. – NASDAQ:PULM - TradingView
Enterprise value to EBITDA forward of Pulmatrix Inc – TRADEGATE:2PU - TradingView
PULM Q2 2025 Earnings: Clinical‑Stage Biotech Reports Loss Per Share of $0.42, No RevenueEBITDA Estimate Trend - dars.gov.et
Price to earnings forward of Pulmatrix Inc – TRADEGATE:2PU - TradingView
Enterprise value to EBIT forward of Pulmatrix, Inc. – NASDAQ:PULM - TradingView
Pulmatrix Inc (PULM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PULM Q2 2025 Earnings: Net Loss of $0.42 Per Share as Clinical-Stage Biotech Advances PipelineMargin Guidance - DonanımHaber
Pulmatrix Inc (PULM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pulmatrix Inc (PULM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pulmatrix Inc (PULM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pulmatrix Inc (PULM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pulmatrix Inc (PULM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pulmatrix Inc (PULM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pulmatrix Inc (PULM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pulmatrix (NASDAQ: PULM) posts 2025 loss as Cullgen merger to give Cullgen 96.4% - Stock Titan
PULM Q2 2025 Earnings: Net Loss Reported, Stock Rises as Investors Look Past Revenue AbsenceConsensus Forecast Report - newsline.com
PULM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Pulmatrix Q2 2025 Earnings: Loss Per Share of $0.42 as Clinical Pipeline AdvancesEarnings Preview - newsline.com
Pulmatrix Q2 2025 Earnings: Net Loss of $0.42 per Share as Biotech Continues Pipeline DevelopmentReturn On Capital - newsline.com
PULM Q2 2025 Earnings: Clinical-Stage Biotech Reports EPS of -$0.42Revenue Inflection Point - newsline.com
Pulmatrix Inc. (PULM) Q2 2025 Earnings: Narrowing Losses Amid Clinical MilestonesCore Business Growth - newsline.com
Preclinical data: PTC-2105 boosts lean mass; Pulmatrix (NASDAQ: PULM) merger on track - Stock Titan
Pulmatrix (PULM) registers 490,910 shares for resale including 36,364 dividends - Stock Titan
PULM Q2 2025 Earnings: EPS Loss of -$0.42 on No Revenue; Stock Declines 2.27%Healthcare Earnings Report - DonanımHaber
Pulmatrix Stock Slides As Eos Merger Clock Starts To Matter For PULM Holders - Bez Kabli
PULM Q2 2025 Earnings: Reported Loss of $0.42 per Share as Company Advances Pipeline - dars.gov.et
PULM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Pulmatrix (PULM) Gains 1.47% as Shares Approach Key Resistance LevelIntraday Trade Ideas - The Legal Advocate
Pulmatrix Inc. (PULM) Edges Higher as Stock Gains 3.68% – Key Levels in FocusProfitability Factor - The Legal Advocate
Pulmatrix Inc. (PULM) Holds Steady at $1.34 as Key Support and Resistance Levels TightenIsland Reversal - The Legal Advocate
Pulmatrix Inc. (PULM) Faces Modest Decline as Stock Tests Key Support LevelsCall Flow Alert - dars.gov.et
Pulmatrix Q2 2025 Earnings: Loss Per Share Widens Amidst No Revenue DisclosureSocial Trade Signals - Newser
Pulmatrix Q2 2025 Earnings: Clinical-Stage Biotech Posts Net Loss of $0.42 per Share, Stock Rises 7.87% - The Legal Advocate
Pulmatrix (PULM) Reports Predictable Q2 2025 — EPS $-0.42 On TargetTrading Community - Newser
Pulmatrix, Inc. Q1 2026 10-Q Report: Financial Results, Merger with Eos SENOLYTIX, and Going Concern Risks - Minichart
Pulmatrix Releases Q1 2026 Financial Results - AlphaStreet
Press Release: Pulmatrix Announces First Quarter 2026 Financial Results - Moomoo
Pulmatrix Announces Q1 2026 Financial Results and Merger Agreement with Eos SENOLYTIX - Minichart
PULM: Merger with Eos SENOLYTIX announced; Q1 net loss narrows, cash at $3.3M - TradingView
Pulmatrix, Inc. 1Q 2026: Net loss $(1.17M), EPS $(0.32) — 10-Q Summary - TradingView
Pulmatrix Q1 net loss narrows, clinical development on hold - TradingView
Pulmatrix reports Q1 2026 net loss $1.17M, cash $3.3M and announces merger agreement with Eos SENOLYTIX - TradingView
Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Pulmatrix (PULM) Q1 2026 shows tight cash, Eos merger and 94% pro forma dilution - Stock Titan
Pulmatrix (NASDAQ: PULM) Q1 loss, $1M raise and Eos merger plan - Stock Titan
Pulmatrix Announces First Quarter 2026 Financial Results - Fidelity
5.60%
0.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):